BRPI0517272A - derivados de pirimidina bicìclicos de inibição de hiv - Google Patents

derivados de pirimidina bicìclicos de inibição de hiv

Info

Publication number
BRPI0517272A
BRPI0517272A BRPI0517272-1A BRPI0517272A BRPI0517272A BR PI0517272 A BRPI0517272 A BR PI0517272A BR PI0517272 A BRPI0517272 A BR PI0517272A BR PI0517272 A BRPI0517272 A BR PI0517272A
Authority
BR
Brazil
Prior art keywords
substituted
alkyl
amino
optionally substituted
halo
Prior art date
Application number
BRPI0517272-1A
Other languages
English (en)
Inventor
Paul Adriaan Jan Janssen
Jerome Emile Georges Guillemont
Mika L Paugam
Bruno Francois Marie Delest
Jan Heeres
Paulus Joannes Lewi
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of BRPI0517272A publication Critical patent/BRPI0517272A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

DERIVADOS DE PIRIMIDINA BICìCLICOS DE INIBIçãO DE HIV. Os inibidores de replicação de HIV de fórmula (I) N-óxidos, sais de adição farmaceuticamente aceitáveis, aminas quartenárias ou formas estereolsoméricas destes, em que -a˜=a-a =a¬ 4¬- é -GH=CH-CH=GH-, -N=CH-CHGH-, -N=CH-N=CH-, -NCH- CHN-, -N=N-CH=CH-; -b˜=b-b=b¬ 4¬- e -CH=CH-CH=CH-, -N=CH-CH=CH-, -N=GH-N=CH-, -N=CH-CH=N-, -N=N- GHCH-; n e m é 0,1, 2, 3 e em certos casos também 4; R¬1¬ é hidrogênio;arila; formila; C~ 1-6~alquilcarbonila; C~ 1-6~alquila opcionalmente substituida; C~ 1-6~alquilóxicarbonila; R é OH; halo; C~ 1-6~alquila opcionalmente substituida, C~ 2-6~alquenila ou C~ 2-6~alquinila; carbonila substituida; carboxila; CN; nitro; amino; amino substituído; polialometila; polialometiltio;-S(=O)~ p~R¬ 6¬ ; C(=NH)R¬ 6¬; R¬ 2a¬ é CN; amino; amino substituído; C~ 16~alquila opcionalmente substituida; halo; C~ 1-6~alquiIóxi opcionalmente substituído; carbonila substituida; -CH=N-NH-C(=O)-R¬ 16¬; C~ 1-6~alquilóxiC~ 1-6~aIquila opcionalmente substituida; C~ 2-6~alqueniía ou C~ 2-6~alquiniía substituida; -C(=N-O-R¬ 8¬)-C~ 1-4~alquila; R¬ 7¬ ou -X-R¬ 7¬; R¬ 3¬ é CN; amino; C~ 1-6~aIquila; halo; C~ 1-6~alquiíóxi opcionalmente substituído; carbonila substituida; -CH=N-NH-C(=O)-R¬ 16¬; C~ 1-6~alquiIa substituida; C~ 16~alquilóxiC~ 1-6~alquila opcionalmente substituida; C~ 2-6~alquenila ou C~ 2-6~alquinila substituida; -C(=N-O-R~ 8~)-C~ 1-4~alquila; R¬ 7¬; -X-R¬ 7¬; R¬ 4¬ é halo; OH; C~ 1-6~aIquiIa, C~ 2-6~alquenila ou C~ 2-6~alquinila opcionalmente substituida; C~ 3-7~acicloalquila; C~ 1-6~alquilóxi; CN; nitro; polialoC~ 1-6~alquila; poliaíoC~ 1-6~alquilóxi; carbonila substituida; formila; amino; mono- ou di(C~ 1-4~alquil)amino ou R¬ 7¬; -A-B- é -CR¬ 5¬=N-, -N=N-, -CH~ 2~-CH~ 2~-, -CS-NH-, -CO-N H-, -CH=CH-; composições farmacêuticas compreendem estes, métodos para a preparação destes compostos e composições; o emprego destes compostos para a prevenção ou o tratamento de infecção de HIV.
BRPI0517272-1A 2004-10-29 2005-10-27 derivados de pirimidina bicìclicos de inibição de hiv BRPI0517272A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04105419 2004-10-29
PCT/EP2005/055589 WO2006045828A1 (en) 2004-10-29 2005-10-27 Hiv inhibiting bicyclic pyrimidine derivatives

Publications (1)

Publication Number Publication Date
BRPI0517272A true BRPI0517272A (pt) 2008-10-07

Family

ID=34929789

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517272-1A BRPI0517272A (pt) 2004-10-29 2005-10-27 derivados de pirimidina bicìclicos de inibição de hiv

Country Status (16)

Country Link
US (5) US8153640B2 (pt)
EP (1) EP1807430B1 (pt)
JP (1) JP5118972B2 (pt)
KR (1) KR20070085286A (pt)
CN (1) CN101048410B (pt)
AR (1) AR051410A1 (pt)
AU (1) AU2005298637B8 (pt)
BR (1) BRPI0517272A (pt)
CA (1) CA2577588C (pt)
ES (1) ES2508766T3 (pt)
IL (1) IL180963A (pt)
MX (1) MX2007005159A (pt)
RU (1) RU2403254C2 (pt)
TW (1) TW200630370A (pt)
WO (1) WO2006045828A1 (pt)
ZA (1) ZA200703444B (pt)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7759342B2 (en) 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
AU2006244195B2 (en) 2005-05-05 2012-03-15 Ardea Biosciences, Inc. Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV
WO2007104053A2 (en) * 2006-03-09 2007-09-13 Pharmacopeia, Inc. 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders
TWI398252B (zh) * 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
MX337906B (es) 2006-10-19 2016-03-28 Signal Pharm Llc Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
RU2009118963A (ru) * 2006-10-20 2010-11-27 Н.В. Органон (Nl) Пурины в качестве ингибиторов ркс-тета
MX2009005881A (es) 2006-12-13 2009-06-12 Hoffmann La Roche Derivados de 2-(piperidin-4-il)-4-fenoxi o fenilamino-pirimidina como inhibidores de la transcriptasa inversa no nucleosida.
US8093246B2 (en) 2006-12-14 2012-01-10 Lexicon Pharmaceuticals, Inc. O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer
ES2389752T3 (es) 2007-12-14 2012-10-31 Ardea Biosciences, Inc. Inhibidores de la transcriptasa inversa
PE20091485A1 (es) * 2008-02-06 2009-10-26 Novartis Ag DERIVADOS DE PIRROLO-[2,3-d]-PIRIMIDINA COMO INHIBIDORES DE CINASAS
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
US8153790B2 (en) 2009-07-27 2012-04-10 Krizmanic Irena Process for the preparation and purification of etravirine and intermediates thereof
SG10201500511TA (en) 2009-10-26 2015-03-30 Signal Pharm Llc Methods Of Synthesis And Purification Of Heteroaryl Compounds
CN102115452A (zh) * 2009-12-30 2011-07-06 上海特化医药科技有限公司 (e)-3-(3-取代-5-甲基苯基)丙烯腈及其制备方法
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
WO2011135578A1 (en) 2010-04-28 2011-11-03 Chetan Balar Composition comprising chitin and tinosporin for use in the treatment of viral diseases
PH12014500869A1 (en) 2011-10-19 2014-06-30 Signal Pharm Llc Treatment of cancer with tor kinase inhibitors
KR102040997B1 (ko) 2011-12-02 2019-11-27 시그날 파마소티칼 엘엘씨 7-(6-(2-히드록시프로판-2-일)피리딘-3-일)-1-((트랜스)-4-메톡시시클로헥실)-3,4-디히드로피라지노[2,3-b]피라진-2(1H)-온, 그의 고체 형태의 제약 조성물 및 그의 사용 방법
ES2655264T3 (es) * 2012-01-28 2018-02-19 Merck Patent Gmbh Derivados de triazolo[4,5-d]pirimidina
EP2817029B1 (en) 2012-02-24 2019-07-10 Signal Pharmaceuticals, LLC Methods for treating non-small cell lung cancer using tor kinase inhibitor combination therapy
EP2872492B1 (en) * 2012-07-12 2018-01-31 Hetero Research Foundation Process for the preparation of rilpivirine using a novel intermediate
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
PE20151995A1 (es) 2013-01-16 2016-01-13 Signal Pharm Llc Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos
MX2015009952A (es) 2013-02-08 2015-10-05 Celgene Avilomics Res Inc Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos.
EP2964648B1 (en) 2013-03-05 2016-11-16 Merck Patent GmbH 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
US9630966B2 (en) 2013-04-17 2017-04-25 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
CA2909579A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
US9505764B2 (en) 2013-04-17 2016-11-29 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
CA2909629C (en) 2013-04-17 2022-12-13 Signal Pharmaceuticals, Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
CN105377299B (zh) 2013-04-17 2018-06-12 西格诺药品有限公司 用于治疗前列腺癌的包含二氢吡嗪并-吡嗪化合物和雄激素受体拮抗剂的组合疗法
CA2908742C (en) 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
WO2014180524A1 (en) 2013-05-06 2014-11-13 Merck Patent Gmbh Macrocycles as kinase inhibitors
NZ629486A (en) 2013-05-29 2017-11-24 Signal Pharm Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
CN105828822B (zh) 2013-08-14 2019-10-18 诺华股份有限公司 用于治疗癌症的组合疗法
BR112016005199B1 (pt) 2013-08-23 2022-02-22 Neupharma, Inc Certos compostos químicos, composições, e métodos
WO2015038417A1 (en) * 2013-09-10 2015-03-19 Asana Biosciences, Llc Compounds for regulating fak and/or src pathways
WO2015160882A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
ES2823756T3 (es) 2014-04-16 2021-05-10 Signal Pharm Llc Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
WO2016010886A1 (en) 2014-07-14 2016-01-21 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
CR20170077A (es) 2014-08-04 2017-06-26 Nuevolution As Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
EP3179858B1 (en) 2014-08-13 2019-05-15 Celgene Car Llc Forms and compositions of an erk inhibitor
BR112017013440A2 (pt) 2014-12-24 2018-01-09 Gilead Sciences, Inc. compostos de isoquinolina para o tratamento de hiv
SG11201705192PA (en) 2014-12-24 2017-07-28 Gilead Sciences Inc Fused pyrimidine compounds for the treatment of hiv
TWI699355B (zh) 2014-12-24 2020-07-21 美商基利科學股份有限公司 喹唑啉化合物
EP3270694A4 (en) * 2015-02-17 2018-09-05 Neupharma, Inc. Certain chemical entities, compositions, and methods
MX388576B (es) 2016-06-07 2025-03-20 Jacobio Pharmaceuticals Co Ltd Derivados heterociclicos novedosos utiles como inhibidores de shp2.
WO2018035061A1 (en) 2016-08-15 2018-02-22 Neupharma, Inc. Certain chemical entities, compositions, and methods
EA202190196A1 (ru) 2017-03-23 2021-08-31 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
TWI787284B (zh) 2017-06-22 2022-12-21 美商西建公司 以b型肝炎病毒感染表徵之肝細胞癌之治療
US20210393623A1 (en) 2018-09-26 2021-12-23 Jacobio Pharmaceuticals Co., Ltd. Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
MX2021003904A (es) 2018-10-05 2021-10-26 Annapurna Bio Inc Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor apj.
US20210380540A1 (en) * 2018-10-25 2021-12-09 Minakem Process for the preparation of rilpivirine
UY38994A (es) 2019-12-20 2021-07-30 Nuevolution As Compuestos activos frente a receptores nucleares
MX2022007265A (es) 2019-12-20 2022-09-09 Nuevolution As Compuestos activos frente a receptores nucleares.
PE20242348A1 (es) 2020-02-19 2024-12-16 Pharmasyntez Agentes antivirales para el tratamiento y la prevencion de la infeccion por vih
AU2021245397A1 (en) 2020-03-31 2022-10-20 Nuevolution A/S Compounds active towards nuclear receptors
WO2021198956A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
CN111303162B (zh) * 2020-04-16 2021-01-22 天津法莫西医药科技有限公司 一种2-氯-7-环戊基-7H-吡咯并[2,3-d]嘧啶-6-羧酸的制备方法
JP2023533016A (ja) 2020-07-11 2023-08-01 ファイザー・インク 抗ウイルス性ヘテロアリールケトン誘導体
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
KR20250101955A (ko) * 2023-12-27 2025-07-04 주식회사 에이조스바이오 신규 퓨린계 화합물 및 이의 용도

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD21593A (pt) *
DE21593C (de) Dr. LÖWIG, Prof. in Breslau Verfahren zur Darstellung von Aetznatron und Aetzkali durch Glühen von Strontiumcarbonat oder Kaliumcarbonat mit Eisenoxyd
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
JPS5962594A (ja) * 1982-09-30 1984-04-10 Ss Pharmaceut Co Ltd ３，５―ジ置換―トリアゾロピリミジン誘導体
BR9611562A (pt) 1995-11-23 1999-03-02 Janssen Pharmaceutica Nv Misturas sólidas de ciclodextrinas preparadas via extrusão sob fusão
NO311614B1 (no) 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
EP0945447A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
EA002973B1 (ru) 1998-03-27 2002-12-26 Янссен Фармацевтика Н.В. Производные пиримидина в качестве ингибиторов репликации вируса иммунодефицита человека
SK287270B6 (sk) * 1998-11-10 2010-05-07 Janssen Pharmaceutica N. V. Derivát pyrimidínu
AU783981C (en) 2000-05-08 2007-05-03 Janssen Pharmaceutica N.V. HIV replication inhibitors
ES2314224T3 (es) * 2002-03-07 2009-03-16 F. Hoffmann-La Roche Ag Inhibidores pirimidina y piridina biciclicos de p38 quinasa.
GB0219746D0 (en) * 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
MXPA05007503A (es) * 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
MXPA05011710A (es) 2003-05-05 2006-01-23 Hoffmann La Roche Derivados de pirimidina con actividad de crf.
AU2004260738B2 (en) 2003-07-16 2009-07-16 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
EP1781659B1 (en) 2003-07-16 2008-11-05 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
CN1918158B (zh) * 2004-02-14 2011-03-02 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
WO2005107760A1 (en) 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation

Also Published As

Publication number Publication date
MX2007005159A (es) 2007-06-26
AU2005298637A8 (en) 2012-12-06
AU2005298637B8 (en) 2012-12-06
CN101048410B (zh) 2010-06-23
US20160355519A1 (en) 2016-12-08
ES2508766T3 (es) 2014-10-16
EP1807430A1 (en) 2007-07-18
US20180009819A1 (en) 2018-01-11
US20180016281A1 (en) 2018-01-18
WO2006045828A1 (en) 2006-05-04
RU2007119784A (ru) 2008-12-10
CA2577588C (en) 2013-09-10
US20080085907A1 (en) 2008-04-10
TW200630370A (en) 2006-09-01
IL180963A (en) 2015-06-30
US10072015B2 (en) 2018-09-11
AR051410A1 (es) 2007-01-10
US9487518B2 (en) 2016-11-08
EP1807430B1 (en) 2014-07-23
CA2577588A1 (en) 2006-05-04
US10077270B2 (en) 2018-09-18
AU2005298637A1 (en) 2006-05-04
US20120190697A1 (en) 2012-07-26
KR20070085286A (ko) 2007-08-27
JP2008517978A (ja) 2008-05-29
US9802943B2 (en) 2017-10-31
AU2005298637B2 (en) 2012-06-28
CN101048410A (zh) 2007-10-03
US8153640B2 (en) 2012-04-10
JP5118972B2 (ja) 2013-01-16
IL180963A0 (en) 2007-07-04
ZA200703444B (en) 2008-11-26
RU2403254C2 (ru) 2010-11-10

Similar Documents

Publication Publication Date Title
BRPI0517272A (pt) derivados de pirimidina bicìclicos de inibição de hiv
TW200626560A (en) HIV inhibiting 5-carbo-or heterocyclic substituted pyrimidines
WO2006035067A3 (en) Hiv inhibiting 5-heterocyclyl pyrimidines
AP1610A (en) HIV replication inhibiting pyrimidines.
TW200510339A (en) HIV replication inhibiting pyrimidines and triazines
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
WO2003063864A3 (fr) Composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
MY144655A (en) Pyrimidine urea derivatives as kinase inhibitors
BRPI0507497A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, e, métodos para prevenir e/ou tratar distúrbios mediados por receptor de mglur5 e para inibir a ativação de receptores de mglur5
UA85541C2 (ru) Карбаматные производные хинуклидина и фармацевтическая композиции, которая содержит эти соединения
PT892793E (pt) Derivados 2-cianoiminoimidazolo inibidores da pde iv
UA86776C2 (ru) Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и применение
TW200504029A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
CL2009001267A1 (es) Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis.
NO20062150L (no) Nye ketooksadiazolderivater som katepsinhibitorer
TW200504030A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
TW200626561A (en) HIV inhibiting 5-substituted pyrimidines
MY138996A (en) 4-amino-5-cyanopyrimidine derivatives
NO20055997L (no) Diarylmetylidenpiperidinderivater og deres anvendelse som opiodreseptoragonister
EP1747200B8 (en) Alkaloid compounds and their use as anti-malarial drugs
SE0402763D0 (sv) Nitro indazole derivatives
BRPI0416588A (pt) uso farmacêutico adicional
TH78460A (th) 5-ซับสทิทิวเทด พิริมิดีนที่ยับยั้ง hiv
TH79598A (th) อนุพันธ์ของไบไซคลิคพิริมิดีนซึ่งยับยั้งเอชไอวี

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: TIBOTEC PHARMACEUTICALS (IE)

B25D Requested change of name of applicant approved

Owner name: JANSSEN R AND D IRELAND (IE)

B25A Requested transfer of rights approved

Owner name: JANSSEN SCIENCES IRELAND UC (IE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]